Combined therapy In some recent studies, interferon (10MU) was given three times a week for *** 16 weeks, and gamasidine was given 100mg daily for 24 weeks, with an effective rate of 29%. In contrast, the effective rate of single drug was 18% ~ 19%, but the difference was not statistically significant.
Antisense oligodeoxynucleotides and ribozyme antisense oligodeoxynucleotides block gene expression through hybridization between antisense strand and antisense strand of HBV DNA. In a recent study, antisense oligodeoxynucleotides inhibited the replication and gene expression of DHBV in Beijing duck for a long time. Ribozyme represents another molecular mechanism to inhibit virus replication. They are antisense oligodeoxynucleotide catalysts that can cleave RNA at specific sites.
The clinical outcome of immunomodulation of acute HBV infection depends on the quality and intensity of host antiviral response. Exactly, HBV in infected hepatocytes may be eliminated by cytotoxic T lymphocytes (CTL), and the possible mechanisms are as follows: ① antigen activated CTL directly kills HBV, leading to the destruction of infected hepatocytes; ② Cytokines secreted by ②②CTL (IFN-γ and TNF-α) can eliminate HBV through noncellular lysis, leading to virus destruction (not destroying hepatocytes), and can eliminate HBV in a large number of hepatocytes by inhibiting virus replication and gene expression. Tolerance is virus-specific, not universal immunosuppression. Many experimental studies show that CD8 ++ and MHCⅰ type ⅰ CTL can clear the virus in infected cells. Therefore, T cell HBeAg epitope vaccine can be used to treat chronic HBV infection.
Thymosin α- 1 can increase the levels of endogenous IFN-α and γ, and also increase IL-2. It can also increase the expression of IL-2 receptor and enhance the proliferation and activity of CD3, CD4, CD8 and NK cells. In HBV infected duck hepatocytes, thymosin α- 1 seems to reduce viral replication, especially at the level of viral protein expression. It is safe, but it needs subcutaneous injection. The results of four studies showed that after 6 months of treatment (1.6mg twice a week), HBeAg and HBV DNA turned negative and ALT decreased to normal in 36% patients. In contrast, only 1 1 1 untreated patients in the control group were effective.